Publicações

  


Publicações das pesquisadoras da Ziel Biosciences em revistas especializadas. Para bibliografia completa acesse os links abaixo:

Caroline Brunetto de Farias: http://lattes.cnpq.br/7436592001738094

Daniela Baumann Cornelio: http://lattes.cnpq.br/3166040182045785

1- PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.

Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, Lenz G, Roesler R, Schwartsmann G, Osvaldt AB, Hainaut P, Ashton-Prolla P.
Invest New Drugs. 2014 Oct;32(5):783-94. doi: 10.1007/s10637-014-0090-9. Epub 2014 May 20.

2 - Genomic instability in human lymphocytes from male users of crack cocaine.

de Freitas TA, Palazzo RP, de Andrade FM, Reichert CL, Pechansky F, Kessler F, de Farias CB, de Andrade GG, Leistner-Segal S, Maluf SW.
Int J Environ Res Public Health. 2014 Sep 26;11(10):10003-15. doi: 10.3390/ijerph111010003.

3 - Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Sassi Fde A, Caesar L, Jaeger M, Nör C, Abujamra AL, Schwartsmann G, de Farias CB, Brunetto AL, Lopez PL, Roesler R.
J Mol Neurosci. 2014 Sep;54(1):27-40. doi: 10.1007/s12031-014-0241-7. Epub 2014 Jan 25.

4 - In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.

Dos Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL.
Oncol Rep. 2014 Feb;31(2):955-68. doi: 10.3892/or.2013.2907. Epub 2013 Dec 6.

5 - Effects of Lonomia obliqua caterpillar venom upon the proliferation and viability of cell lines.

Heinen TE, de Farias CB, Abujamra AL, Mendonça RZ, Roesler R, da Veiga AB.
Cytotechnology. 2014 Jan;66(1):63-74. doi: 10.1007/s10616-013-9537-7. Epub 2013 Jan 22.

6 - Neutrality of miniSTR D22S1045 marker by Ewing's sarcoma phenotype.

Silva DS, Raimann PE, Moro T, Picanço JB, Abujamra AL, de Farias CB, Roesler R, Brunetto AL, Alho CS.
Leg Med (Tokyo). 2013 Nov;15(6):335-7. doi: 10.1016/j.legalmed.2013.08.004. Epub 2013 Sep 10.

7 - Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.

Jaeger M, Nör C, de Farias CB, Abujamra AL, Schwartsmann G, Brunetto AL, Roesler R.
Childs Nerv Syst. 2013 Dec;29(12):2145-50. doi: 10.1007/s00381-013-2290-6. Epub 2013 Oct 3.

8 - Antiproliferative activity of the dimeric phloroglucinol and benzophenone derivatives of Hypericum spp. native to southern Brazil.

Pinhatti AV, de Barros FM, de Farias CB, Schwartsmann G, Poser GL, Abujamra AL.
Anticancer Drugs. 2013 Aug;24(7):699-703. doi: 10.1097/CAD.0b013e3283626626.

9 - Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.

Thurow HS, Hartwig FP, Alho CS, Silva DS, Roesler R, Abujamra AL, de Farias CB, Brunetto AL, Horta BL, Dellagostin OA, Collares T, Seixas FK.
Mol Biol Rep. 2013 Aug;40(8):4929-34. doi: 10.1007/s11033-013-2593-4. Epub 2013 May 10.

10 - The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.

Nör C, Sassi FA, de Farias CB, Schwartsmann G, Abujamra AL, Lenz G, Brunetto AL, Roesler R.
Mol Neurobiol. 2013 Dec;48(3):533-43. doi: 10.1007/s12035-013-8441-7. Epub 2013 Mar 21.

11 - Influence of GRPR and BDNF/TrkB signaling on the viability of breast and gynecologic cancer cells.

Cornelio DB, DE Farias CB, Prusch DS, Heinen TE, Dos Santos RP, Abujamra AL, Schwartsmann G, Roesler R.
Mol Clin Oncol. 2013 Jan;1(1):148-152. Epub 2012 Aug 7.

12 - Influence of GRPR and BDNF/TrkB signaling on the viability of breast and gynecologic cancer cells.

Cornelio DB, DE Farias CB, Prusch DS, Heinen TE, Dos Santos RP, Abujamra AL, Schwartsmann G, Roesler R.
Mol Clin Oncol. 2013 Jan;1(1):148-152. Epub 2012 Aug 7.

13 - Ewing's sarcoma: analysis of single nucleotide polymorphism in the EWS gene.

Silva DS, Sawitzki FR, De Toni EC, Graebin P, Picanco JB, Abujamra AL, de Farias CB, Roesler R, Brunetto AL, Alho CS.
Gene. 2012 Nov 10;509(2):263-6. doi: 10.1016/j.gene.2012.08.012. Epub 2012 Aug 20.

14 - BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition.

de Farias CB, Heinen TE, dos Santos RP, Abujamra AL, Schwartsmann G, Roesler R.
Biochem Biophys Res Commun. 2012 Aug 24;425(2):328-32. Epub 2012 Jul 25.

15 - The gastrin-releasing peptide receptor as a marker of dysplastic alterations in cervical epithelial cells.

Cornelio DB, Meurer L, Schwartsmann G, Roesler R.
Oncology. 2012;82(2):90-7. doi: 10.1159/000335955. Epub 2012 Feb 9.

16 - BDNF/TrkB signaling as an anti-tumor target.

Roesler R, de Farias CB, Abujamra AL, Brunetto AL, Schwartsmann G.
Expert Rev Anticancer Ther. 2011 Oct;11(10):1473-5. doi: 10.1586/era.11.150. No abstract available.

17 - Effect of mangiferin, a naturally occurring glucoxylxanthone, on fear memory in rats.

Andreu GL, Maurmann N, Reolon GK, de Farias CB, Delgado R, Roesler R.
Arzneimittelforschung. 2011;61(7):382-5.

18 - The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.

Nör C, de Farias CB, Abujamra AL, Schwartsmann G, Brunetto AL, Roesler R.
Childs Nerv Syst. 2011 Jun;27(6):897-901. doi: 10.1007/s00381-011-1439-4. Epub 2011 Apr 6.

19 - Regulation of E-cadherin expression by growth factor receptors in cancer cells.

Nery LR, Rodrigues MM, Rosemberg DB, Bogo MR, De Farias CB, Abujamra AL, Schwartsmann G, Roesler R, Vianna MR.
J Surg Oncol. 2011 Aug 1;104(2):220-1. doi: 10.1002/jso.21898. Epub 2011 Feb 28. No abstract available.

20 - Current and emerging molecular targets in glioma.

Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, Schwartsmann G.
Expert Rev Anticancer Ther. 2010 Nov;10(11):1735-51. doi: 10.1586/era.10.167. Review.

21 - Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels.

Goulart BK, de Lima MN, de Farias CB, Reolon GK, Almeida VR, Quevedo J, Kapczinski F, Schröder N, Roesler R.
Neuroscience. 2010 Jun 2;167(4):969-73. doi: 10.1016/j.neuroscience.2010.03.032. Epub 2010 Mar 22.

22 - Mangiferin, a naturally occurring glucoxilxanthone improves long-term object recognition memory in rats.

Pardo Andreu GL, Maurmann N, Reolon GK, de Farias CB, Schwartsmann G, Delgado R, Roesler R.
Eur J Pharmacol. 2010 Jun 10;635(1-3):124-8. doi: 10.1016/j.ejphar.2010.03.011. Epub 2010 Mar 19.

23 - HER2 as a cancer stem-cell target.

Roesler R, Cornelio DB, Abujamra AL, Schwartsmann G.
Lancet Oncol. 2010 Mar;11(3):225-6. doi: 10.1016/S1470-2045(09)70404-8. No abstract available.

24 - BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells.

Schmidt AL, de Farias CB, Abujamra AL, Kapczinski F, Schwartsmann G, Brunetto AL, Roesler R.
J Mol Neurosci. 2010 Mar;40(3):303-10. doi: 10.1007/s12031-009-9221-8. Epub 2009 Jul 30.

25 - BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer.

Brunetto de Farias C, Rosemberg DB, Heinen TE, Koehler-Santos P, Abujamra AL, Kapczinski F, Brunetto AL, Ashton-Prolla P, Meurer L, Reis Bogo M, Damin DC, Schwartsmann G, Roesler R. Oncology. 2010;79(5-6):430-9. doi: 10.1159/000326564. Epub 2011 Apr 8.

26 - Emerging therapeutic agents for cervical cancer.

Cornelio DB, Roesler R, Schwartsmann G.
Recent Pat Anticancer Drug Discov. 2009 Nov;4(3):196-206. Review.

27 - Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist.

de Farias CB, Stertz L, Lima RC, Kapczinski F, Schwartsmann G, Roesler R.
Protein Pept Lett. 2009;16(6):650-2.

28 - Devic's neuromyelitis optica and pregnancy: distinction from multiple sclerosis is essential.

Cornelio DB, Braga RP, Rosa MW, Ayub AC.
Arch Gynecol Obstet. 2009 Sep;280(3):475-7. doi: 10.1007/s00404-008-0918-7. Epub 2009 Jan 17.

29 - Phosphodiesterase-4 inhibition and brain tumor growth.

Schmidt AL, de Farias CB, Abujamra AL, Brunetto AL, Schwartsmann G, Roesler R.
Clin Cancer Res. 2009 May 1;15(9):3238; author reply 3238-9. doi: 10.1158/1078-0432.CCR-09-0097.

30 - Gastrin-releasing peptide receptors regulate proliferation of C6 Glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism.

Flores DG, de Farias CB, Leites J, de Oliveira MS, Lima RC, Tamajusuku AS, Di Leone LP, Meurer L, Brunetto AL, Schwartsmann G, Lenz G, Roesler R.
Curr Neurovasc Res. 2008 May;5(2):99-105.

31 - Gastrin-releasing peptide receptor expression in cervical cancer.

Cornelio DB, Meurer L, Roesler R, Schwartsmann G.
Oncology. 2007;73(5-6):340-5. doi: 10.1159/000134478. Epub 2008 May 23.

32 - Targeting the bombesin/gastrin-releasing peptide receptor to treat sepsis.

Cornelio DB, Dal-Pizzol F, Roesler R, Schwartsmann G.
Recent Pat Antiinfect Drug Discov. 2007 Nov;2(3):178-81. Review.

33 - Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

Cornelio DB, Roesler R, Schwartsmann G.
Ann Oncol. 2007 Sep;18(9):1457-66. Epub 2007 Mar 9. Review.

34 - Targeting the epidermal growth factor receptor in colorectal cancer: a potential therapeutic role for gastrin-releasing peptide receptor antagonists.

Fernando A, Brunetto de Farias C, Roesler R, Schwartsmann G.
Oncology. 2007;72(3-4):160-1. Epub 2007 Dec 21. No abstract available.

35 - Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines.

Brondani Da Rocha A, Regner A, Grivicich I, Pretto Schunemann D, Diel C, Kovaleski G, Brunetto De Farias C, Mondadori E, Almeida L, Braga Filho A, Schwartsmann G.
Int J Oncol. 2004 Sep;25(3):777-85.

Contato:

  •